Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer

Inclusion Criteria:

* Patients must have histologically or cytologically confirmed inoperable or metastatic adenocarcinoma of the stomach or lower third of the oesophagus refractory or intolerable to standard therapy.
* Patients must have measurable or evaluable disease.
* Age \>= 201years
* ECOG performance status of 0 to 2
* Life expectancy at least 3 months
* Patients must have normal organ and marrow function as defined below:
* absolute neutrophil count \>=1,500/mcL
* platelets \>=100,000/mcL
* total bilirubin within normal institutional limits
* AST(SGOT)/ALT(SGPT) \<=2.5 X institutional upper limit of
* Normal creatinine within normal institutional limits
* Patients must be HLA-A\*2402
* Patients must have recover from all reversible treatment toxicity from prior chemotherapy, radiotherapy or surgery.
* The effects of OTSGC-A24 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients receiving any other investigational agents.
* History of significant gastrointestinal bleeding that required intervention within the prior 1 month is ineligible; inherited bleeding diathesis or coagulopathy.
* Serious non healing wound and peptic ulcer disease
* Previous history of intestinal perforation
* Invasive procedures defined as follows (Insertion of a vascular access device is not considered major/minor surgery):
* Major surgical procedure, open biopsy or significant traumatic injury =28 days prior to -registration
* Anticipation of need for major surgical procedures during the course of the study
* Core biopsy \<=7 days
* Minor surgery \<=2 weeks
* Symptomatic CNS metastasis
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension (systolic \>150 mmHg and/or diastolic \>100 mmHg), symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction/cerebrovascular event (\<=6 months prior to study entry), cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, long term systemic immunosuppressant or corticosteroid.
* Women who are breast-feeding or pregnant are excluded from this study